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Abstract
Atrial fibrillation (AF) represents the most common sustained heart rhythm 
abnormality. It presents in paroxysmal and persistent forms. The pathogenesis of 
AF is still debatable with several proposed mechanisms. The main pathway for 
diagnosis of AF is through electrocardiographic record. Treatment strategies can 
be divided into two strategies: rate and rhythm control. For rhythm control, antiar-
rhythmic drugs, direct current cardioversion, and electrophysiological ablation 
are used, while for rate control, chronotropic drugs are being used, while AV node 
ablation is required in order to reduce rapid ventricular rate, which is often observed 
in patients with AF. The rhythm control strategy implies the use of cardioversion to 
convert AF to normal, sinus rhythm. Cardioversion can be either pharmacological 
or electrical. Rate control strategy can be implied to patients with permanent AF but 
should also imply for the patients with paroxysmal AF when relapse occurs. Rapid 
ventricular rates can cause palpitations or even a syncope and other rate-related 
symptoms; however, these high ventricular rates lead to degradation of left ventricle 
performance, mitral regurgitation, and further dilatation of the left atrium. The 
main antiarrhythmic drugs used in treatment of AF are propafenone, flecainide, 
beta-blockers, amiodarone, dronedarone, dofetilide, vernakalant, and ranolazine.
Keywords: atrial fibrillation, antiarrhythmic drugs, propafenone, flecainide, 
amiodarone, dronedarone, dofetilide
1. Introduction
Atrial fibrillation (AF) represents the most common sustained heart rhythm 
abnormality, one of the most common cardiovascular diseases and a major cause 
of stroke in developed countries. It presents in paroxysmal and persistent forms. 
Paroxysmal form of AF is defined with a duration less than 7 days and can termi-
nate spontaneously, while persistent forms are further classified as persistent and 
permanent forms with a duration of greater than 7 days with only difference in 
possibility of conversion to normal, sinus rhythm; in persistent form conversion to 
sinus rhythm is possible, while in permanent form, conversion to normal rhythm is 
not possible.
Atrial fibrillation can occur in isolated form (without associated comorbidities), 
yet it is more commonly seen with other cardiovascular diseases, cardiomyopathies, 
hypertension, diabetes mellitus, and obesity. When seen in association with these 
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comorbidities, atrial fibrillation deeply affects quality of life and increases mortal-
ity and morbidity [1].
AF affects 1–1.5% of the population in the developed world with approximately 
3 million people with a diagnosis of AF in the USA [2]. The prevalence and inci-
dence of AF are sharply increased with age with a rise from 0.7% in the age group 
of 55–59 years to 17.8% in those aged 85 years or above. With such a big prevalence, 
treatment of AF represents a significant burden to the healthcare systems. The data 
from the US databases from 2001 showed the estimated total annual cost of AF 
treatment at 6.65 billion US$ [3].
The pathogenesis of AF is still debatable with several proposed mechanisms. The 
traditional theory suggests multiple reentrant atrial activation by migrating wave-
lets and contraction rate of 350–900 beats per minute [4, 5]. Several animal models 
have shown that AF is triggered by a focal source, which rapidly fires signals and is 
usually found in superior pulmonary veins. It stimulates multiple wavelet reentry 
mechanism within the atrial substrate or engages a spiral or rotor for the reentry 
[6–8]. Research also showed that in patients with AF, there is a sympathetic pre-
dominance over parasympathetic; however, in certain patients, it can be character-
ized with predominance of vagal or an adrenergic form of AF [9]. Besides that, AF 
can be related to temporary causes, such as drugs, alcohol, thyrotoxicosis, surgery, 
myocardial infarction, myocarditis, pericarditis, pulmonary embolism, and others. 
Obesity, sleep apnea and metabolic syndrome have also been linked to AF. Besides 
temporary causes, AF can be associated with permanent heart disease, such as 
valvular disease in which context AF is called valvular AF. Coronary heart disease, 
heart failure, hypertension, left ventricular hypertrophy, all forms of cardiomy-
opathies, and cardiac tumors have been associated with a high incidence of AF and 
carry a worse prognosis when compared to isolated form of AF. As mentioned, AF 
can occur in isolated or familial forms, without apparent identifiable underlying 
disease [3].
The main pathway for diagnosis of AF is through electrocardiographic record. 
A first-detected or recorded episode of AF is defined as the first one, despite the 
fact whether the patient was symptomatic or not and the possibility of the previ-
ous undetected episodes. Presentation of the patients with AF can differ, from 
with vague non-specific symptoms to thromboembolic consequences. Generally 
speaking, symptoms of AF depend of the rate of ventricular response, irregularity 
of the rhythm, functional status, duration of AF, and many more factors. As previ-
ously noted, the diagnosis of AF requires 12-lead electrocardiographic documenta-
tion or ambulatory Holter monitoring (especially in patients with daily paroxysms, 
but its usefulness is less in patients who have paroxysms at intervals more than 
24 h). In patients with paroxysm with intervals that are greater than 24 h, implant-
able loop record devices, such as Reveal LINQ or CONFIRM, are used, as well as 
atrial high-rate episode recordings in patients with implantable dual-chamber 
pacemakers [1, 3].
2. Treatment strategies
Before initiating a treatment in patient with AF, we should first consider the 
probability of reoccurrence and/or persistence of the arrhythmia as well as patient 
symptomatology. Treatment strategies can be rate and rhythm control. For rhythm 
control, antiarrhythmic drugs, direct current cardioversion, and electrophysiologi-
cal ablation are used, while for rate control, chronotropic drugs are being used, 
while AV node ablation is required in order to reduce rapid ventricular rate response 
which is often observed in patients with AF.
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2.1 Rhythm control strategy
The rhythm control strategy implies the use of cardioversion to convert AF to 
normal, sinus rhythm. Cardioversion can be either pharmacological or electrical. 
Depending on the factors that lead to AF, not all attempts of cardioversion are 
successful, with about 50% of patients reverting to AF within a year of cardiover-
sion [10]. Pharmacological cardioversion is preferred over electrical, especially 
in patients who present with AF within 48 h, while electrical is a standard proce-
dure for AF with duration of more than 48 h. Rhythm control strategy by using 
antiarrhythmic drugs is an essential part in management of AF whose goals are 
prevention of reoccurrence and modification of recurrences by making them less 
symptomatic, less frequent, and less sustained [3].
Patients with persistent AF should be considered for either pharmacological 
or direct current cardioversion (DCCV) despite symptomatology, unless there are 
contraindications. Antiarrhythmic drugs may be prescribed to patients before and/
or after successful DCCV for a period of time in order to prevent reoccurrence of 
AF. The use of antiarrhythmic drugs before DC conversion can also improve suc-
cessfulness of DC conversion by prolongation of atrial refractoriness [11]. Besides 
antiarrhythmic drugs, patients may also require antithrombotic therapy. The 
recommendations for anticoagulation therapy are the same for both pharmacologi-
cal and electrical cardioversion.
Antiarrhythmic drugs express their effect by blocking ion channels by which 
they affect atrial or junctional automaticity or refractoriness. By this mechanism, 
antiarrhythmic drugs suppress the trigger of AF (frequent atrial premature beats, 
rapid atrial tachycardia, etc.). Besides that, these drugs decrease excitability and 
conduction velocity by discouraging reentry mechanism or by changing autonomic 
stimulation (such as beta-blockers).
Side effect profiles, safety, and underlying heart diseases and their nature influ-
ence the choice of antiarrhythmic drugs; however, drugs with the greatest effects are 
also the ones that have bigger proarrhythmic effects and negative inotropic effects.
In the most cases, optimal beta-blockade represents the first line or is already 
administered for underlying heart diseases or for ventricular rate control in AF. If 
beta-blockers fail in rhythm control strategy or are contraindicated, a specific 
antiarrhythmic drug may be used. The selection of specific antiarrhythmic drug 
depends mostly on associated cardiovascular disease. Typically, patients can be 
divided into four categories: those with no or minimal heart disease, hypertensive 
heart (with or without significant left ventricular hypertrophy), ischemic heart dis-
ease, and heart failure. Also, besides this classification, patients can also be divided 
into two categories according to the presence of heart failure with reduced ejection 
fraction (ejection fraction <35%) or not (ejection fraction >35%) [1].
In patients with no or minimal heart disease, generally flecainide and propafe-
none are the first-line drugs. Dofetilide and dronedarone are the second-line drugs; 
since monitoring is required and expenses are high, amiodarone is reserved as the 
last-line therapy, while sotalol is being avoided because of the need for hospitaliza-
tion and acquired long QT syndrome. Figure 1 shows the optimal choice of antiar-
rhythmic drugs according to the underlying heart disease.
For patients who have left ventricular hypertrophy and AF, only two drugs are 
available: dronedarone and amiodarone. Thus, in patients with severe hypertrophy, 
there is only sufficient clinical experience with amiodarone. Sotalol and dofetilide 
should be avoided in the presence of significant left ventricular hypertrophy, since 
there is significant risk of QT prolongation and development of malignant arrhyth-
mias. Antiarrhythmics of class Ic (propafenone and flecainide) are also not used 
because of proarrhythmic effect.
Epidemiology and Treatment of Atrial Fibrillation
4
Patients with coronary artery disease and paroxysmal or persistent AF should be 
treated with sotalol, amiodarone, or dronedarone, since they are both anti-ischemic 
and antiarrhythmic; however, sometimes sotalol and dronedarone are avoided 
because of proarrhythmic risk or progression to permanent AF. Propafenone 
and flecainide are contraindicated in patients with coronary artery disease since 
increased mortality was observed in the Cardiac Arrhythmia Suppression Trial 
(CAST) in patients with post-myocardial infarction with active ischemia [12].
For patients with heart failure and paroxysmal and persistent AF, only amioda-
rone and dronedarone can be considered for all grades of heart failure. However, 
dronedarone should be avoided in patients with recently unstable New York Heart 
Association (NYHA) class IV heart failure, particularly in patients with ejection 
fraction of left ventricle less than 35%. Even though there is no or little alternative 
to amiodarone for patients with heart failure in Europe, there are some concerns 
regarding the use of amiodarone in NYHA class III heart failure.
For acute pharmacological cardioversion, oral or intravenous antiarrhythmics 
with class Ic (flecainide and propafenone) or III (amiodarone, ibutilide, and dofeti-
lide) can be used or new, atrial selective agent—vernakalant [3]. Depending on the 
agent as well as factors that lead to the development of AF, the rate of successful 
conversion to normal, sinus rhythm differs [13]. Out-of-hospital conversion of AF 
can also be achieved in patients with persistent AF with pill-in-the-pocket strategy 
which consists of self-administration of single oral dose of class Ic antiarrhythmics 
on the onset of symptoms of AF.
Assessment of rhythm control strategy should not be led by the presence or 
absence of symptoms since many clinical trials concluded that there is often little 
or no association between symptoms and reoccurrence of AF; therefore, prolonged 
monitoring is advised. In situation where patient is adequately anticoagulated, 
frequent visits are not necessary; however, if the initiation of anticoagulation 
therapy is based on the frequency of arrhythmia episodes, detailed and prolonged 
monitoring is required (24 h ECG Holter monitoring, 48 h ECG Holter monitoring, 
7-day ECG Holter monitoring or implantable loop recorded implantation).
Figure 1. 
Optimal choice of antiarrhythmic drug in different clinical settings [modified from Shenasa and Camm [1]].
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2.2 Rate control strategy
In patients with permanent AF, control of the ventricular response rate is 
important, since a lot research suggested that high heart rates were associated with 
poor outcomes in the terms of mortality. Besides patients with permanent AF, the 
rate control strategy should be also implied for the patients with paroxysmal AF 
when relapse occurs, especially if the patients are symptomatic or hemodynamically 
compromised by it. Rapid ventricular rates can cause palpitations or even a syncope 
and other rate-related symptoms; however, these high ventricular rates lead to 
degradation of left ventricle performance, mitral regurgitation, and further dilata-
tion of the left atrium. If the heart rate exceeds 125 beats per minute, even a normal 
ventricle may dilate, but in patients with impaired left ventricle function, even less 
heart rates can cause further dilatation. On the other hand, the loss of atrial con-
traction (observed in patients with AF), which approximately accounts for 20–30% 
of the total stroke volume of left ventricle, leads to further reduction in cardiac 
output. Besides these two mechanisms, irregularity in ventricle rhythm addition-
ally impairs left ventricle function. That is why the goal of rate control strategy is 
heart rate below 115 beats per minute in light and/or moderate physical activity and 
below 80 beats per minute in rest. However, sometimes ventricle rates at rest do not 
adequately represent effective control during exercise [1, 14].
Principles of rate control strategy may be easy to implement in patients with 
permanent AF and then in those with paroxysmal or persistent form since the con-
trol of the heart rate in arrhythmia and in sinus rhythm can and are often different, 
especially in patients with dysfunction of sinus node. In these circumstances, symp-
tomatic bradycardia with long sinus pauses can occur. In these patients, heart rate 
support is needed, and implantation of dual-chamber pacemaker is often needed. 
Therefore, the main reason for rate control strategy in patients with intermittent AF 
is failure to find adequate blend of the effect on heart rate during AF and when sinus 
rhythm occurs. It should be noted that effects of different antiarrhythmic drugs 
have different effects on AV node, whereas beta-blockers have less marked effect on 
AV node than calcium channel blockers and cause sinus bradycardia more often.
Three different classes of drugs are being used for rate control: digitalis, calcium 
channel blockers, and beta-blockers. Beta-blockers and calcium channel blockers are 
preferred over digitalis and should be used in most of the patients with chronic AF 
without heart failure, while in patients with chronic AF and heart failure, digoxin 
or amiodarone should be used in order to control ventricular rate. By using digitalis, 
adequate control of exercise heart rate is rarely achieved, so in patients who are mildly 
to moderately physically active, there will be no benefit. Digitalis is also less effica-
cious than amiodarone and calcium channel blockers and in some studies even beta-
blockers. Most patients should be treated with beta-blocker (usually beta-2 specific 
beta-blocker like bisoprolol, metoprolol, carvedilol, or nebivolol) or calcium channel 
blocker with rate-limiting effect, such as verapamil or diltiazem. In patients whom 
adequate control of heart rate is not achieved, a combination of drugs is needed; how-
ever, it is not advised in patients with reduced left ventricle function. Amiodarone 
is reserved as a last-line therapy, especially for patients with heart failure and with 
reduced ejection fraction. It is a powerful and very effective heart rate-limiting drug, 
but many adverse effects are the main drawback of amiodarone therapy [15–18] .
Besides traditional therapy for rate control, in patients with AF and in whom 
rate is not adequately achieved, the use of sotalol and amiodarone can slow the AV 
conduction, but they are not commonly used for long-term rate control because of 
the proarrhythmic risk. In situations where rapid control of heart rate is needed, 
oral administration is not feasible, but intravenous administration of diltiazem 
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can be considered, while in patients without heart failure or accessory pathways, 
intravenous beta-blockers (esmolol, metoprolol, and propranolol), diltiazem, and 
verapamil may be used. If the patient has accessory pathway, only intravenous 
amiodarone is indicated [3].
The doses of drugs used for rate control strategy are given in Table 1 [1].
If the rate control cannot be established, interventional approach can also be 
performed by ablation of AV node/His bundle alongside with implantation of 
pacemaker.
For the assessment of rate control strategy, palpation of the radial pulse with 
auscultation of heart murmurs, and electrocardiography can be easily obtained 
and provide sufficient information for most of the patients. If needed, 6 min walk 
test or 24 h ambulatory Holter ECG monitoring can be implemented giving more 
reliable information regarding resting and exercise heart rate.
2.3 Direct current cardioversion
Prior to DC conversion it is important to evaluate each patient for appropriate-
ness, maintaining normal, sinus rhythm thereafter, as well as probability of success-
ful cardioversion [3]. Several factors can influence success of the cardioversion and/
or reoccurrence of AF, such as age, underlying valve disease, duration of AF, size of 
the left atrium, low functional class, and possibility of concomitant administration 
of antiarrhythmic drugs. DC cardioversion has been extensively used with vitamin 
K-dependent anticoagulants (VKAs), while more recently direct oral anticoagulants 
(DOACs) have been also used for thromboembolic prevention in patients who are 
undergoing DC conversion.
DC cardioversion is being performed short-acting general anesthetics or under 
heavy sedation, while assessment of potassium levels and therapeutic levels of digoxin 
is indicated in all patients, since hypokalemia and supratherapeutic levels of digoxin can 
precipitate ventricular arrhythmias in patients with DC cardioversion. Synchronization 
is used to avoid discharging on T waves since it can result in ventricular arrhythmias. 
Drug Average dose Clinical setting Adverse effects
Digoxin Loading dose: 
250 mcg every 2 h; 
up to 1500 mcg
Maintenance dose: 
125–250 mcg daily
As monotherapy 
in elderly patients; 
not physically active 
patients
Bradycardia; AV blocks; 
proarrhythmic
Bisoprolol 5–10 mg daily Patients with coronary 
artery disease; heart 
failure
Hypotension; bradycardia, 
especially in paroxysmal AF; AV 
blocks; impairment of pulmonary 
function in chronic obstructive 
pulmonary disease or asthma
Metoprolol 50–200 mg daily
Carvedilol 25–100 mg daily
Nebivolol 5–10 mg daily
Sotalol 80–320 mg daily Recurrent AF Not recommended in permanent 
AF; bradycardia; QT prolongation; 
proarrhythmic
Verapamil 80–360 mg daily Patients with chronic 
obstructive pulmonary 
disease and asthma
Hypotension; AV blocks; heart 
failure
Diltiazem 120–360 mg daily
Amiodarone 200 mg daily Recurrent AF; heart 
failure
Bradycardia; AV blocks; QT 
prolongation; proarrhythmic
Table 1. 
Average doses of antiarrhythmic drugs used for rate control in AF [1].
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If monophasic DC cardioversion is being used, an initial 300 J biphasic shock or 150 J 
monophasic shock should be given, followed by the second 200 J monophasic or 300 J 
biphasic shock if the first one fails. If the second shock fails, the third and final one can 
be delivered with the same magnitude as the second one. Biphasic shocks at high output 
are more successful than monophasic shocks at the same output [3].
2.4 Ablation strategies
Currently, the main way of nonpharmacological rhythm control is catheter 
ablation of AF, without the risk of long-term antiarrhythmic therapy maintain-
ing normal, sinus rhythm. It has been shown that catheter ablation significantly 
improves LV function, symptoms, exercise capacity, and quality of life. In addition, 
some meta-analyses have shown that catheter ablation was superior to antiarrhyth-
mic drugs for the control of AF. The benefit of catheter ablation was even greater in 
paroxysmal AF when compared to medical therapy [18]. Catheter ablation was also 
better than antiarrhythmics in terms of higher rates of freedom from both AF and 
antiarrhythmic medications [19]. However, no mortality benefit was observed in 
patients who have undergone catheter ablation of AF, so the procedure is currently 
reserved for patients with symptomatic AF [20].
Besides catheter ablation, one more way of treatment of AF includes surgical 
ablation of AF. The procedure involves creating series of incisions in both the left 
and the right atria, by which propagation of sinus impulse is directed through both 
atria and at the same time disabling multiple macro-reentrant circuits. Currently, 
the standard surgical technique has been replaced with linear epicardial ablation 
using unipolar or bipolar radiofrequency ablation, cryoablation, laser, high-
frequency ultrasound, and microwave energy. Also, surgical instrumentation now 
enables minimally invasive approaches through mini-thoracotomies with video 
assistance. Stand-alone surgical and epicardial AF ablation may be considered for 
patients who are symptomatic and were refractory to one or more attempts of cathe-
ter ablation or for patients who are not candidates for catheter ablation. Hence, there 
are no studies that compared effects of surgical and catheter ablation of AF, degree 
of patient discomfort, longer hospitalizations, and the risk of bleeding following left 
atrial appendage excision, patients prefer catheter ablation to surgical [20].
2.5 Anticoagulant therapy
Anticoagulation therapy is one of the cornerstones in management of patients 
with AF, since the most common consequence of AF is stroke.
The recommendations for anticoagulation therapy are the same for both 
pharmacological and electrical cardioversion. CHA2DS2-VASc risk score is being 
used in order to assess whether the patient is in need for anticoagulation therapy, 
while HAS-BLED score assesses the risk of bleeding in patients on anticoagulation 
therapy. Anticoagulation therapy can be either with the use of direct oral anticoagu-
lants (DOACs), such as apixaban, rivaroxaban, dabigatran, or edoxaban, or the use 
of vitamin K-dependent anticoagulants (VKAs) such as warfarin and acenocuma-
rol. In patient with VKAs, assessment of INR is very important and should always 
be within 2.0–3.0 unless there are other cofactors (mechanical valves, etc.).
3. Pharmacology of antiarrhythmic drugs
The choice of antiarrhythmic drug and its superiority of one over another are not 
well investigated due to many reasons, such as enrolment of patients with different 
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underlying heart diseases or suboptimal design. Doses, indications, and the main 
adverse effects of the most commonly used antiarrhythmics are given in Table 2 [1].
3.1 Flecainide and propafenone
As antiarrhythmic drugs of class Ic, propafenone and flecainide are frequently 
used for rhythm control in patients with AF and no or minimal underlying heart 
disease (such as heart failure, left ventricular hypertrophy, coronary artery disease, 
or previous myocardial infarction).
Flecainide expresses its effect with potent blockade of sodium and potassium 
channels, however, not prolonging the QT interval.
Propafenone has similar effects as quinidine, although it possesses some beta-
blocking activity without prolonging the action potential.
In clinical trials that investigated recurrence rates, both propafenone and 
flecainide reduced the recurrence rate by 70%. Co-administration of AV-slowing 
agents such as beta-blockers is advised because of the possibility of organization of 
AF into atrial flutter. When directly compared, there was no superiority of propafe-
none over flecainide [21].
Drug Dose Clinical setting Adverse effects
Flecainide 100–
200 mg 
two times 
per day
Minimal or no structural heart 
disease
Bradycardia; AV blocks; 
organization into atrial flutter; 
deterioration of renal function
Flecainide XL 200 mg 
one time 
per day
Propafenone 150–
300 mg 
three times 
per day
Bradycardia; AV blocks; 
organization into atrial flutter; 
new onset of myocardial 
ischemia; metallic taste
Propafenone 
SR
225–
425 mg 
two times 
per day
Sotalol 80–160 mg 
two times 
per day
Stable coronary artery disease 
without previous myocardial 
infarction; hypertension 
without significant left ventricle 
hypertrophy
Bradycardia; AV blocks; 
proarrhythmic; potassium level 
disorders
Dofetilide 125–
500 mcg 
two times 
per day
Previous myocardial infarction; 
heart failure
Torsade de pontes; bradycardia; 
AV blocks; proarrhythmic
Amiodarone 100–
200 mg 
one time 
per day
Heart failure; hypertrophic 
cardiomyopathy; significant left 
ventricular hypertrophy
Bradycardia; AV blocks; 
thyrotoxic; pulmonary fibrosis; 
hepatic toxicity; eye toxicity, skin 
rash; abdominal pain; peripheral 
edema; dyspnea
Dronedarone 400 mg 
two times 
per day
Heart failure NYHA I–II; 
coronary artery disease; left 
ventricular hypertrophy
Bradycardia; AV blocks; 
diarrhea; rash
Table 2. 
Doses, indications, and adverse effects of the most commonly used antiarrhythmic drugs [1].
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3.2 Beta-blockers
The most effective antiarrhythmic drugs in prevention of AF are considered 
as beta-blockers. Even though they are mainly used in rate control strategy, in AF 
caused by thyrotoxicosis, after cardiac surgery or any adrenergically mediated AF, 
they represent the first-choice therapy. Between the groups of beta-blockers, there 
is limited evidence of superiority of one over another. Some, such as carvedilol, 
may be more potent because of synergistic effect on ion channels as well as 
adrenergic blockade; however, in direct comparison to bisoprolol, no benefit was 
observed [22, 23].
3.3 Sotalol
Sotalol, an antiarrhythmic drug of class III and beta-blocker, offers additional 
benefit of slowing heart rate during reoccurrences in AF episodes. It is recom-
mended for use in patients with AF and stable coronary artery disease without 
previous myocardial infarction and/or dysfunction of the left ventricle and patients 
with AF and hypertension without significant left ventricle hypertrophy.
When compared with amiodarone, it showed inferior results with 30% of 
patients remaining in sinus rhythm after 2 years of therapy, while in the group of 
amiodarone, 60% remained in sinus rhythm. In comparison with antiarrhythmics 
class Ic, it showed similar effects [24–26].
Bradycardia and hypotension represent the most common side effects, while 
prolongation of QT with proarrhythmic effect was less common. Due to its rela-
tively simple pharmacokinetics, it has very few drug interactions; however, it 
should be noted that sotalol decreases the threshold for cardiac defibrillation.
3.4 Dofetilide
Dofetilide is also one of the antiarrhythmic drugs of class III, but unlike sotalol 
or antiarrhythmics class Ic, it is recommended for use in patients with previ-
ous myocardial infarction and in patients with heart failure. It does not produce 
blockade of other potassium or sodium channels, but the rate of recovery from 
the blockade is slow; therefore, the extent of blockade shows little dependence on 
stimulation frequency.
Dofetilide has a dose-dependent effect; increased dose resulted in increased 
proportion of patients converted to sinus rhythm. However it comes with the cost. 
Its major concern is development of torsade de pontes which is also dose-related 
and often occurs in the first days after dofetilide initiation; therefore, in-hospital 
initiation is mandatory. Treatment with dofetilide should be initiated based on the 
rate-corrected QT interval (QTc) and serum electrolytes. A baseline QTc greater 
than 450 ms, bradycardia with heart rate less than 50 beats per minute, and hypo-
kalemia are relative contraindications.
Since 80% of oral dose is being eliminated unchanged by the kidneys and its 
dose-related side effects, dofetilide dosage must be based on the estimated creati-
nine clearance [27].
3.5 Amiodarone
Amiodarone is one of the most commonly used antiarrhythmic worldwide, as a 
result of its broad spectrum of antiarrhythmic action.
Amiodarone markedly prolongs the duration of action potential, thus prolong-
ing the QT interval. Despite its belonging to class III of antiarrhythmics, it also 
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blocks inactivated sodium channels and has weak adrenergic and calcium channel 
blocking effect by which it slows down heart rate and AV node conduction.
It has great potential to maintain sinus rhythm in patients with underlying 
cardiovascular conditions. Its effect on rhythm control has been largely investi-
gated; however, one main drawback of amiodarone use is its side effects. Looking 
on proarrhythmic effects, it has low potential to induce torsade de pontes; however, 
non-cardiac side effects are numerous. It did not show effect on all-cause mortality; 
however, it can be used in management of AF in clinical settings of heart failure, 
hypertrophic cardiomyopathy, and significant left ventricular hypertrophy caused 
by hypertension [28].
Amiodarone side effects are a result of dose and accumulation in many tissues 
(lungs, liver, skin, and even heart). It also blocks the peripheral conversion of 
thyroxine to triiodothyronine and may result in hyperthyroidism and hypothyroid-
ism, which in many cases are the most frequent side effects.
3.6 Dronedarone
Besides sotalol, dofetilide, and amiodarone, dronedarone is also a member of class 
III of antiarrhythmic and has been widely used in prevention of recurrence of parox-
ysmal or persistent AF and is also effective in slowing ventricular rated during AF.
It is structural analog of amiodarone in which iodine atoms have been removed, 
therefore eliminating action on thyroxine metabolism.
Large clinical trials have demonstrated that dronedarone reduced relative risk 
of hospitalizations due to cardiovascular causes and death, differed the time to the 
first hospitalization for cardiovascular disease or death from any cause, and signifi-
cantly reduced deaths from cardiovascular diseases [29]. Based on the antiarrhyth-
mic trial with dronedarone in moderate to severe heart failure evaluating morbidity 
decrease (ANDROMEDA) study with patients with severe congestive heart failure, 
which was stopped ahead of time because excess death was revealed in droneda-
rone group, dronedarone should not be used in patients with severe heart failure 
[30]. Therefore, dronedarone is currently recommended for use in patients with 
paroxysmal AF with reducing the need of hospitalization for cardiovascular events 
or after conversion of persistent AF; however, it should be avoided in patients with 
permanent AF or advanced heart failure (Table 3).
3.7 Other antiarrhythmics
Ranolazine, an antianginal agent, belongs to more recently developed antiar-
rhythmics or recently investigated as antiarrhythmic drug. It blocks several ion 
channels and foremost on atrial level. Clinical investigations have demonstrated 
that it has potential to facilitate electrical cardioversion in refractory patients, 
efficacy as the pill-in-the-pocket approach, and enhancing pharmacological 
cardioversion with its synergistic effect with amiodarone [31, 32]. When combined 
with dronedarone, it also showed promising results [33]. However, further studies 
are needed to explore its full antiarrhythmic potential.
Vernakalant is relatively a new antiarrhythmic drug, and its main effect is 
achieved by blocking the sodium channels. Besides sodium channels it also blocks 
other channels and mild QT interval prolongation. Besides oral, vernakalant can 
also be administered intravenously, making it a preferable choice for rapid conver-
sion of AF. It has been investigated for converting recent-onset AF. In some clinical 
trials, it showed superior efficacy when compared to amiodarone for acute conver-
sion of AF [34]. It is recommended in patients with AF and no or minimal ischemic 
or structural heart disease and may be considered in patients with AF and mild to 
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Vaughan-
Williams class
Mechanism of action Drug Dose Clinical setting Adverse effects
I class Ia class Moderate blockade of 
sodium channels
Quinidine 200–600 mg 
three times per 
day
Brugada syndrome; atrial fibrillation and 
flutter as last-line drug
Diarrhea; prolongation of QTc; enhances 
digitalis toxicity; proarrhythmic
Disopyramide 400–800 mg two 
to three times 
per day
Ventricular arrhythmias Proarrhythmic; dry mouth; blurred vision; 
hypotension; increased incidence of heart 
failure
Ib class Weak blockade of sodium 
channels
Lidocaine 1–1.5 mg/kg i.v. Ventricular arrhythmias in acute 
myocardial infarction
Hypotension; edema; methemoglobinemia
Mexiletine 200–300 mg 
three times per 
day
Ventricular arrhythmias Proarrhythmic; bradycardia; AV blocks
Ic class Strong blockade of sodium 
channels
Flecainide 100–200 mg two 
times per day
Minimal or no structural heart disease Bradycardia; AV blocks; organization into atrial 
flutter; deterioration of renal function
Propafenone 150–300 mg 
three times per 
day
Bradycardia; AV blocks; organization into atrial 
flutter; new onset of myocardial ischemia; 
metallic taste
II class Beta 1 selective Bisoprolol 5–10 mg daily Patients with coronary artery disease; 
heart failure
Hypotension; bradycardia, especially in 
paroxysmal AF; AV blocks; impairment of 
pulmonary function in chronic obstructive 
pulmonary disease or asthma
Beta 1 selective Metoprolol 50–200 mg daily
Nonselective Carvedilol 25–100 mg daily
Strong beta 1 selectivity and 
vasodilatation
Nebivolol 5–10 mg daily
III class Blockade of potassium 
channels and increasing 
effective refractory period
Sotalol 80–320 mg daily Stable coronary artery disease without 
previous myocardial infarction; 
hypertension without significant left 
ventricle hypertrophy
Bradycardia; AV blocks; proarrhythmic; 
potassium level disorders
Epidem
iology and T
reatm
ent of A
trial Fibrillation
12
Vaughan-
Williams class
Mechanism of action Drug Dose Clinical setting Adverse effects
Dofetilide 125–500 mcg two 
times per day
Previous myocardial infarction; heart 
failure
Torsade de pontes; bradycardia; AV blocks; 
proarrhythmic;
Amiodarone 100–200 mg one 
time per day
Heart failure; hypertrophic 
cardiomyopathy; significant left 
ventricular hypertrophy
Bradycardia; AV blocks; thyrotoxic; pulmonary 
fibrosis; hepatic toxicity; eye toxicity, skin rash, 
abdominal pain; peripheral edema; dyspnea
Dronedarone 400 mg two 
times per day
Heart failure NYHA I–II; coronary artery 
disease; left ventricular hypertrophy
Bradycardia; AV blocks; diarrhea; rash
IV class Slow non-dihydropyridine 
calcium channel blockers
Verapamil 80–360 mg daily Patients with chronic obstructive 
pulmonary disease and asthma
Hypotension; AV blocks; heart failure
Diltiazem 120–360 mg 
daily
Table 3. 
Antiarrhythmic drugs, Vaughan-Williams class, mechanism of action, doses, clinical settings, and adverse effects [1].
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moderate structural heart disease as well as post-cardiac surgery AF. It is also more 
effective than flecainide and propafenone, again in recent-onset AF, and is well 
tolerated while to most common side effects including paresthesia, dysgeusia, dizzi-
ness, sneezing, and nausea [35, 36].
4. Conclusions
AF represents as one of the most common cardiovascular diseases and a major 
cause of stroke in developed countries. Treatment strategies can be divided into 
two strategies: rate and rhythm control. For rhythm control, antiarrhythmic drugs, 
direct current cardioversion, and electrophysiological ablation are used, while for 
rate control, chronotropic drugs are being used, while AV node ablation is required 
in order to reduce rapid ventricular rate which is often observed in patients with AF. 
Table 3 summarizes all antiarrhythmics with Vaughan-Williams class, mechanism 
of action, doses, clinical settings, and adverse effects.
Patients with paroxysmal or persistent form of AF should be considered for 
either pharmacological or DC despite symptomatology, unless there are contraindi-
cations. Rapid ventricular rates can cause palpitations or even a syncope and other 
rate-related symptoms; however, these high ventricular rates lead to degradation of 
left ventricle performance, mitral regurgitation, and further dilatation of the left 
atrium; therefore, if the conversion is not achievable, patients should be treated 
with rate control strategy.
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